Extract is raw material. CPG (consumer packaged goods) manufacturing is where extract becomes product. This is where pharmaceutical science meets consumer goods—where you translate cannabinoid content into stable, bioavailable, shelf-stable products that meet regulatory requirements across multiple jurisdictions and deliver consistent consumer experience at scale.

Our Revivid product line produces millions of units annually across 20+ SKUs. That scale requires systems, standards, and deep formulation expertise. I'll walk you through how professional cannabis manufacturing actually works.

cGMP and Quality Systems: Non-Negotiable Foundation

Current Good Manufacturing Practice (cGMP) is the regulatory standard for pharmaceutical and CPG manufacturing in the U.S. and internationally. The requirement isn't just "make good products"—it's comprehensive documented systems covering every aspect of production:

cGMP compliance isn't optional if you want regulatory approval in developed markets. Brazil's ANVISA explicitly requires cGMP. Japan's MHLW requires cGMP or equivalent standards. The EU requires cGMP for medical products. U.S. state regulators increasingly require cGMP.

ISO 9001 certification (quality management system) complements cGMP. ISO 9001 is a third-party audit demonstrating that your company systematically manages quality. We maintain both cGMP compliance and ISO 9001 certification at our facilities. The overlap is significant—cGMP is more specific to pharma, ISO 9001 is broader but provides independent verification.

Product Form Considerations: The Formulation Decision

The same extract can be formulated into multiple product forms. Each has different manufacturing requirements, different bioavailability profiles, different shelf-life challenges, and different regulatory pathways.

1. Oil Tinctures

Tinctures are cannabis extracts dissolved in a carrier oil (typically coconut oil, MCT oil, or hemp seed oil). They're the simplest formulation: mix extract with carrier oil, optionally add vitamin E as an antioxidant, fill into glass bottles with dropper caps.

Advantages:

Challenges:

2. Softgel Capsules

Extract is encapsulated in soft gelatin shells, creating precise-dose units. This is pharmaceutical-standard packaging.

Advantages:

Challenges:

3. Gummies and Edibles

Extract is incorporated into gummy or edible matrix (typically gelatin or pectin-based, with sugar, corn syrup, or alternative sweeteners). Each gummy contains precise cannabinoid dose.

Advantages:

Challenges:

4. Topicals

Extract is incorporated into cream, lotion, or salve base for skin application. Formulation requires transdermal penetration science—getting cannabinoids through the skin barrier.

Advantages:

Challenges:

The Bioavailability Challenge

Bioavailability is the percentage of administered cannabinoids that reaches systemic circulation. It's not 100% for any oral form. Your 10mg CBD gummy doesn't deliver 10mg bioavailable CBD—it delivers somewhere between 4-8mg depending on formulation and individual physiology.

Factors affecting bioavailability:

This is why nano-emulsification technology has emerged as a game-changer. Nano-emulsions break cannabinoid droplets into tiny particles (100-200nm), dramatically increasing surface area for absorption. Nano-emulsified products achieve 60-80% bioavailability—dramatically higher than conventional formulations.

The trade-off: nano-emulsification requires specialized equipment and expertise. Products are more expensive to produce. But for clinical efficacy (particularly for medical products), nano-emulsification is standard.

Stability Testing and Shelf Life

A product in your hand today must remain stable—potency unchanged, no degradation—for months or years in consumer's cabinet. That requires stability testing:

Testing includes potency (HPLC analysis of cannabinoid content), appearance, smell, taste, and microbial load. A successful stability study demonstrates that the product maintains 90%+ of labeled potency throughout its shelf life.

For international markets, stability data is mandatory for product authorization. Brazil's ANVISA requires minimum 12-month stability data. Japan's MHLW requires 24-month data. The EU typically requires 36-month data for pharmaceutical products.

Production Scale and Efficiency

Small batch production (1,000-10,000 units) is doable with basic equipment and limited automation. But scaling to millions of units annually requires different approach: specialized equipment, automation, and process optimization.

Our Revivid facility produces millions of tinctures, softgels, gummies, and topicals annually through:

The investment is significant ($500K-$2M depending on equipment and automation level). But unit cost drops dramatically at scale. Hand-filled tinctures might cost $3 per unit to produce. Automated production drops cost to $0.30-0.50 per unit.

Regulatory Pathways: Different Markets, Different Requirements

Brazil (ANVISA): Pharmaceutical pathway. Products classified as medicines require clinical data, manufacturing authorization, and ongoing pharmacovigilance. Timeline: 18-24 months from application to authorization. Our Revivid line achieved authorization in this pathway.

Japan (MHLW): Strict regulatory pathway. CBD is allowed; THC is prohibited. Products require medical device or pharmaceutical classification. Manufacturing must meet Japanese cGMP equivalent standards. Timeline: 12-18 months. We pioneered the first authorized pathway in 2015.

EU (Novel Food): Products containing CBD must complete Novel Food authorization. Safety data required, manufacturing compliance required. Timeline: 18-36 months. EU permits higher THC content than Japan but has complex cross-border regulations.

U.S. (State-by-state): Requirements vary dramatically. Some states require pharmaceutical-level compliance, others minimal oversight. Federal prohibition of THC-containing products remains, though CBD is increasingly accepted. Landscape is fragmented.

The Manufacturing Advantage

In a commoditized cannabis market, manufacturing excellence is your moat. Any operator can grow cannabis. Many can extract. But professional CPG manufacturing—cGMP facilities, ISO 9001 certification, regulatory approvals, stability data, quality assurance—separates operators from manufacturers.

That's where Hammer Consulting brings value. We build the systems, develop the formulations, guide the regulatory pathways. The result: products that pass inspection, achieve market authorization, and earn consumer trust.